Increased spending on oral anticancer drugs should ideally be driven by increased use because of rising access to care and expanding drug indications.^1,2 Yet, prices have risen faster than inflation and are not necessarily reflective of novelty or efficacy.^2,3 This study weighs the proportional associations of rising drug costs and use with increased Medicare Part D spending for a cohort of oral anticancer drugs used from 2013 through 2017.

中文翻译：

---

从 2013 年到 2017 年，成本上升和口服抗癌药使用与医疗保险 D 部分支出的关联

由于获得护理的机会增加和药物适应症的扩大，理想情况下，增加口服抗癌药物的支出应由增加使用来推动。^{1 ,2}然而，价格上涨速度快于通货膨胀，并不一定反映新颖性或有效性。^{2 ,3}本研究权衡了 2013 年至 2017 年使用的一组口服抗癌药物的药物成本和使用与医疗保险 D 部分支出增加之间的比例关联。